Stock Events

Ab Science 

$2.7
4
-$0.06-2.33% Wednesday 13:47

Statistics

Day High
0
Day Low
0
52W High
9
52W Low
0
Volume
100
Avg. Volume
48
Mkt Cap
140.59M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

30JunConfirmed
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Q4 2020
Q1 2021
-0.13
-0.09
-0.04
0
Expected EPS
0
Actual EPS
-0.0593

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ABSCF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap83.12B
Gilead Sciences is a biopharmaceutical company that competes with AB Science in the development of treatments for various diseases, including those in oncology and inflammatory diseases, areas where AB Science is also active.
Novartis
NVS
Mkt Cap206.64B
Novartis is a global healthcare company that competes across multiple segments, including those targeted by AB Science, such as cancer and chronic inflammatory diseases, with a broad portfolio of drugs.
AMGEN
AMGN
Mkt Cap144.25B
Amgen is a biotech company focusing on human therapeutics, with products that compete in the oncology and inflammatory disease markets, directly competing with AB Science's research and drug development efforts.
Pfizer
PFE
Mkt Cap147.23B
Pfizer is a research-based biopharmaceutical company with a wide range of products that compete with AB Science, especially in the fields of oncology and immunology.
Roche
RHHBY
Mkt Cap170.92B
Roche Holding AG is a healthcare company that competes with AB Science in developing treatments for various diseases, including cancer and chronic inflammatory conditions, through its biotechnology and pharmaceutical divisions.
Bristol-Myers Squibb
BMY
Mkt Cap99.17B
Bristol-Myers Squibb is a global biopharmaceutical company with a focus on discovering, developing, and delivering innovative medicines that compete with AB Science's portfolio, especially in cancer and immune-inflammatory diseases.
Merck &
MRK
Mkt Cap318.6B
Merck & Co., Inc. is known for its contributions to healthcare and pharmaceuticals, competing with AB Science in areas such as oncology, making it a direct competitor in the development of cancer treatments.
Lilly(Eli) &
LLY
Mkt Cap690.11B
Eli Lilly and Company is a global pharmaceutical company that develops drugs in areas like oncology and autoimmune diseases, competing with AB Science in the development and marketing of treatments for similar conditions.
Regeneron Pharmaceuticals
REGN
Mkt Cap96.81B
Regeneron Pharmaceuticals is a biotechnology company that competes with AB Science in the development of medicines for the treatment of serious medical conditions, including oncology and inflammatory diseases.
Astrazeneca
AZN
Mkt Cap212.54B
AstraZeneca is a multinational pharmaceutical and biopharmaceutical company with a wide range of therapeutic products, competing with AB Science in areas such as oncology and respiratory diseases.

About

Pharmaceuticals: Other
Health Technology
AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company also develops AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase 2 clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. It markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
Show more...
CEO
Employees
89
Country
FR
ISIN
FR0010557264
WKN
000A1CXBG

Listings